O	0	1	A
O	2	13	comparative
O	14	19	study
O	20	22	of
B-intervention	23	33	exemestane
O	34	40	versus
B-control	41	52	anastrozole
O	53	55	in
O	56	64	patients
O	65	69	with
O	70	84	postmenopausal
O	85	91	breast
O	92	98	cancer
O	99	103	with
O	104	112	visceral
O	113	123	metastases
O	123	124	.

O	125	133	Patients
O	134	144	developing
O	145	153	visceral
O	154	160	breast
O	161	167	cancer
O	168	178	metastases
O	179	188	generally
O	189	196	receive
O	197	209	chemotherapy
O	210	216	rather
O	217	221	than
O	222	231	endocrine
O	232	239	therapy
O	239	240	.

O	241	247	Recent
O	248	257	aromatase
O	258	267	inhibitor
O	268	275	studies
O	276	280	have
O	281	289	reported
O	290	298	activity
O	299	301	in
O	302	306	such
O	307	315	patients
O	315	316	;
O	317	326	therefore
O	326	327	,
O	328	332	this
O	333	338	study
O	339	347	formally
O	348	357	evaluated
O	358	369	anastrozole
O	370	373	and
O	374	384	exemestane
O	385	387	in
O	388	402	postmenopausal
O	403	411	patients
O	412	414	in
O	415	419	this
O	420	427	setting
O	427	428	.

B-eligibility	429	443	Postmenopausal
I-eligibility	444	449	women
I-eligibility	450	454	with
I-eligibility	455	463	advanced
I-eligibility	464	470	breast
I-eligibility	471	477	cancer
I-eligibility	478	481	and
I-eligibility	482	483	>
I-eligibility	484	486	or
I-eligibility	487	488	=
I-eligibility	489	490	1
I-eligibility	491	499	visceral
I-eligibility	500	501	(
I-eligibility	501	506	liver
I-eligibility	507	509	or
I-eligibility	510	514	lung
I-eligibility	514	515	)
I-eligibility	516	522	lesion
O	523	527	were
O	528	538	randomized
O	539	541	to
O	542	553	anastrozole
O	554	555	(
O	555	556	1
O	557	559	mg
O	559	560	/
O	560	563	day
O	564	570	orally
O	570	571	)
O	572	574	or
O	575	585	exemestane
O	586	587	(
O	587	589	25
O	590	592	mg
O	592	593	/
O	593	596	day
O	597	603	orally
O	603	604	)
O	605	608	for
O	609	610	>
O	611	613	or
O	614	615	=
O	616	617	8
O	618	623	weeks
O	623	624	.

O	625	628	The
O	629	636	primary
O	637	645	endpoint
O	646	649	was
B-outcome-Measure	650	659	objective
I-outcome-Measure	660	668	response
I-outcome-Measure	669	671	in
I-outcome-Measure	672	680	visceral
I-outcome-Measure	681	688	lesions
O	689	694	based
O	695	697	on
O	698	706	modified
O	707	715	Response
O	716	726	Evaluation
O	727	735	Criteria
O	736	738	in
O	739	744	Solid
O	745	751	Tumors
O	751	752	.

O	753	762	Secondary
O	763	772	endpoints
O	773	781	included
B-outcome-Measure	782	790	clinical
I-outcome-Measure	791	798	benefit
O	799	800	(
O	800	809	objective
O	810	818	response
O	819	823	plus
O	824	830	stable
O	831	838	disease
O	839	840	>
O	841	843	or
O	844	845	=
O	846	849	180
O	850	854	days
O	854	855	)
O	855	856	,
B-outcome-Measure	857	864	overall
I-outcome-Measure	865	873	survival
O	873	874	,
O	875	878	and
B-outcome-Measure	879	886	adverse
I-outcome-Measure	887	893	events
O	893	894	.

O	895	896	A
O	897	902	total
O	903	905	of
B-total-participants	906	909	130
O	910	918	patients
O	919	923	were
O	924	932	enrolled
O	932	933	,
O	934	937	and
B-total-participants	938	941	128
O	942	950	patients
O	951	952	(
B-control-participants	952	954	64
O	955	966	anastrozole
O	966	967	,
B-intervention-participants	968	970	64
O	971	981	exemestane
O	981	982	)
O	983	987	were
O	988	996	included
O	997	999	in
O	1000	1003	the
O	1004	1010	intent
O	1010	1011	-
O	1011	1013	to
O	1013	1014	-
O	1014	1019	treat
O	1020	1028	analysis
O	1028	1029	.

O	1030	1037	Accrual
O	1038	1044	delays
O	1045	1051	caused
O	1052	1057	study
O	1058	1065	closure
O	1066	1072	before
O	1073	1076	the
O	1077	1083	target
O	1084	1094	enrollment
O	1095	1096	(
O	1096	1097	N
O	1098	1099	=
O	1100	1103	200
O	1103	1104	)
O	1105	1108	was
O	1109	1116	reached
O	1116	1117	,
O	1118	1126	limiting
O	1127	1130	the
O	1131	1142	statistical
O	1143	1148	power
O	1149	1151	of
O	1152	1155	the
O	1156	1161	study
O	1161	1162	.

B-outcome	1163	1172	Objective
I-outcome	1173	1181	response
I-outcome	1182	1184	in
I-outcome	1185	1193	visceral
I-outcome	1194	1199	sites
O	1200	1203	was
O	1204	1217	approximately
B-iv-bin-percent	1218	1220	15
I-iv-bin-percent	1220	1221	%
O	1222	1224	in
O	1225	1229	both
O	1230	1236	groups
O	1236	1237	.

B-outcome	1238	1246	Clinical
I-outcome	1247	1254	benefit
I-outcome	1255	1257	in
I-outcome	1258	1266	visceral
I-outcome	1267	1272	sites
O	1273	1276	was
B-cv-bin-percent	1277	1279	32
I-cv-bin-percent	1279	1280	%
O	1281	1283	of
O	1284	1287	the
O	1288	1296	patients
O	1297	1304	treated
O	1305	1309	with
O	1310	1321	anastrozole
O	1322	1325	and
B-iv-bin-percent	1326	1328	38
I-iv-bin-percent	1328	1329	%
O	1330	1332	of
O	1333	1336	the
O	1337	1345	patients
O	1346	1353	treated
O	1354	1358	with
O	1359	1369	exemestane
O	1369	1370	.

B-outcome	1371	1377	Median
I-outcome	1378	1386	survival
O	1387	1390	was
B-cv-cont-median	1391	1393	33
I-cv-cont-median	1393	1394	.
I-cv-cont-median	1394	1395	3
I-cv-cont-median	1396	1402	months
O	1403	1406	and
B-iv-cont-median	1407	1409	30
I-iv-cont-median	1409	1410	.
I-iv-cont-median	1410	1411	5
I-iv-cont-median	1412	1418	months
O	1419	1421	in
O	1422	1425	the
O	1426	1437	anastrozole
O	1438	1441	and
O	1442	1452	exemestane
O	1453	1459	groups
O	1459	1460	,
O	1461	1473	respectively
O	1473	1474	.

O	1475	1485	Toxicities
O	1486	1490	were
O	1491	1498	similar
O	1499	1501	to
O	1502	1507	those
O	1508	1518	previously
O	1519	1527	reported
O	1527	1528	;
O	1529	1536	however
O	1536	1537	,
B-outcome	1538	1547	treatment
I-outcome	1547	1548	-
I-outcome	1548	1555	related
I-outcome	1556	1563	adverse
I-outcome	1564	1570	events
O	1571	1575	were
O	1576	1580	more
O	1581	1589	frequent
O	1590	1594	with
O	1595	1606	anastrozole
O	1607	1608	(
B-cv-bin-percent	1608	1610	41
I-cv-bin-percent	1610	1611	%
O	1611	1612	)
O	1613	1617	than
O	1618	1622	with
O	1623	1633	exemestane
O	1634	1635	(
B-iv-bin-percent	1635	1637	31
I-iv-bin-percent	1637	1638	%
O	1638	1639	)
O	1639	1640	.

O	1641	1645	Both
O	1646	1656	treatments
O	1657	1661	were
O	1662	1671	generally
B-outcome	1672	1676	well
I-outcome	1677	1686	tolerated
O	1687	1689	in
O	1690	1698	patients
O	1699	1703	with
O	1704	1718	postmenopausal
O	1719	1725	breast
O	1726	1732	cancer
O	1733	1737	with
O	1738	1746	visceral
O	1747	1757	metastases
O	1757	1758	.

B-outcome	1759	1767	Efficacy
O	1768	1771	was
O	1772	1779	similar
O	1780	1782	in
O	1783	1787	both
O	1788	1797	treatment
O	1798	1804	groups
O	1805	1808	for
O	1809	1812	all
O	1813	1822	endpoints
O	1822	1823	.

O	1824	1833	Aromatase
O	1834	1844	inhibitors
O	1845	1848	can
O	1849	1851	be
O	1852	1862	considered
O	1863	1865	as
O	1866	1867	a
O	1868	1877	treatment
O	1878	1884	option
O	1885	1887	in
O	1888	1902	postmenopausal
O	1903	1911	patients
O	1912	1916	with
O	1917	1924	hormone
O	1925	1933	receptor
O	1933	1934	-
O	1934	1942	positive
O	1943	1951	visceral
O	1952	1958	breast
O	1959	1965	cancer
O	1966	1976	metastases
O	1976	1977	.
